Evidence map›Paper›PMID 36423023›Full record

ArticleVaccines2022

Hepatitis B, C, and D Virus Infection among Population Aged 10-64 Years in Mongolia: Baseline Survey Data of a Nationwide Cancer Cohort Study.

Davaalkham Dambadarjaa, Otgonbayar Radnaa, Ser-Od Khuyag, Oyu-Erdene Shagdarsuren, Uranbaigali Enkhbayar, Yerkyebulan Mukhtar, Enkh-Oyun Tsogzolbaatar, Gunchmaa Nyam, Shatar Shaarii, Pramil Singh and 3 more

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Davaalkham DambadarjaaSchool of Public Health, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.ORCID 0000-0001-6999-9367
Otgonbayar RadnaaSchool of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Ser-Od KhuyagSchool of Public Health, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Oyu-Erdene ShagdarsurenSchool of Public Health, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Uranbaigali EnkhbayarSchool of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Yerkyebulan MukhtarSchool of Public Health, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Enkh-Oyun TsogzolbaatarSchool of Public Health, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Gunchmaa NyamSchool of Public Health, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.ORCID 0000-0001-9752-4350
Shatar ShaariiSchool of Public Health, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Pramil SinghTransdisciplinary Tobacco Research Program, Loma Linda University Cancer Center, Loma Linda, CA 92354, USA.ORCID 0000-0002-9820-2887
Masaharu TakahashiDivision of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Shimotsuke 329-0498, Japan.
Bira NamdagSchool of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Hiroaki OkamotoDivision of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Shimotsuke 329-0498, Japan.ORCID 0000-0003-0827-0964
Mongolian National University of Medical Sciences · MNJichi Medical University · JPLoma Linda University · US

Funding

Building GIS Capacity into Tobacco Control Research Programs of East AsiaR01TW005964 · FIC · LOMA LINDA UNIVERSITY · PI SINGH, PRAMIL NAND · 2002 to 2021
$2.4M
FIC NIH HHS R01 TW005964
6 · The paper itself

Abstract

Hepatitis B, C, and D virus infections are a major public health problem, and Mongolia has one of the highest prevalences of dual and triple infections in the world. We aimed to determine the seroprevalence of hepatitis infection and dual or triple hepatitis infections among 10-64-year-olds. A questionnaire was used to identify risk factors for hepatitis infection, and seromarkers were measured by the fully automated immunologic analyzer HISCL-5000. Among a total of 10,040 participants, 8.1% of the population aged 10-64 was infected with HBV, 9.4% with HCV, and 0.4% with HBV and HCV, and the prevalence of the disease varied by age, sex, and the area of residence. Young people were particularly unaware of their hepatitis infection status. A small proportion of children aged 10 to 19 years and the majority of adults younger than 30 years were unaware of their HBV and HCV infection. Men were also more likely to be unaware of their HBV and HCV infection status than women. The results suggested that the prevalence of infection in the general population is high and that most people are unaware that they are infected or have become chronic carriers. Identifying mono-, co-, or triple-infection status is critical to prevent the rapid progression of liver disease among the Mongolian population.

Indexed as

hepatitis Bhepatitis CinfectionMongoliaprevalencevirus

Identifiers

PMID36423023
PMCPMC9696522
OpenAlexW4309306161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.